In this edition of Open Interest, we look at how the focus on GLP-1 could reduce household dietary intake and grocery bills.

Eli Lilly & Co. sees 60% sales increase for weight-loss drug in India, tapping into growing demand for anti-obesity solutions ...

Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

Eli Lilly (LLY) increased its sale of Mounjaro, its weight-loss and diabetes drug, by 60% in India in May from April, Satviki Sanjay of Bloomberg ...

Eli Lilly's weight-loss and diabetes drug, Mounjaro, has experienced a 60% sales increase in India between April and May.

Eli Lilly’s diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven ...

Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...